Carlos S. Kase, MD
Emeritus Professor
Boston University School of Medicine
Dept of Neurology

MD, Pontificia Universidad Católica de Chile

Born in Buenos Aires, Argentina, Dr. Carlos Kase earned his MD degree in Santiago, Chile, from the Catholic University of Chile in May 1967. He pursued further training in Neurology and Vascular Neurology at Massachusetts General Hospital in Boston from 1972-1973, and 1977-1978. Dr. Kase is board-certified by the American Board of Psychiatry and Neurology in Neurology (1980) and also board-certified in the subspecialty of Vascular Neurology (2005).

Dr. Kase joined the Department of Neurology at Boston University School of Medicine in 1984, where he is currently Professor of Neurology and Neurologist-in-Chief, Boston Medical Center. Prior to this, he joined Dr. J.P. Mohr in forming the Neurology Department at the University of South Alabama in Mobile, Alabama in 1978.

Dr. Kase's professional and research interests are in cerebrovascular diseases, with a special interest in intracerebral hemorrhage, carotid artery disease and lacunar infarctions. He has been actively involved in performing clinical studies and clinico-pathologic correlations in intracerebral hemorrhage and cerebral infarction. His research activities have included participation in multicenter NIH-sponsored studies such as the Stroke Data Bank (NINCDS), the Warfarin Aspirin Recurrent Stroke Study (WARSS), the Warfarin vs. Aspirin for Symptomatic Intracranial Disease (WASID) Study, the Secondary Prevention of Small Subcortical Strokes (SPS3) study, and the Insulin Resistance Intervention after Stroke (IRIS) trial, as well as in a number of therapeutic clinical trials. In addition, Dr. Kase has participated in the Framingham Study since 1984, where he has led a number of important epidemiological studies on risk factors in stroke.

Dr. Kase has received numerous distinguished honors for his work in cerebrovascular disease, including Honorary Membership to the Spanish Society of Neurology and the Mexican Association of Cerebrovascular Disease. In 2001, he received the C. Miller Fisher Award for Excellence in Stroke, awarded by the American Stroke Association, Massachusetts Affiliate. In 2002 he was awarded the title of Doctor Honoris Causa from the Universidad de Santiago de Compostela, Santiago de Compostela, Spain.

Dr. Kase was recognized as a "Top Doctor" in Neurology by Boston Magazine in 2009, 2010, 2011, 2012 and by U.S. News and World Report in 2011.

Active Staff Privileges
Boston Medical Center

Randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of desmoteplase in acute ischemic stroke
09/01/2009 - 12/31/2014 (PI)
Lundbeck, Inc.

A Phase 2, Randomized, Double Blind Placebo Controlled Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of PF-04360365 (Ponezumab)
10/21/2013 - 11/30/2014 (PI)
Pfizer, Inc.

Personnel Agreement for Research Services of Ethan Treglia
01/01/2011 - 09/30/2012 (PI)
VA Boston Healthcare System

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic D
05/01/2008 - 04/30/2012 (PI)
Schering-Plough Research Institute

12/01/2009 - 01/31/2012 (PI)
University of British Columbia NIH NINDS

PREDICT (Predicting hEmatoma growth anD outcome in Intracerebral hemorrhage using contrast bolus CT) study
11/01/2009 - 10/30/2010 (PI)
University of Calgary

PRoFESS- Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel and Aspirin, With and Without Micardis
09/01/2003 - 08/31/2007 (PI)
Boehringer Ingelheim Pharmaceuticals

DIAS 2: Desmoteplase (INN) In Acute Ischemic Stroke: Phase III
05/17/2005 - 12/31/2006 (PI)
Forest Laboratories, Inc./Forest Research Institute

Management of Atherothrombosis with Clopidogrel in High Risk Patients with Recent Transient Ischemic of Ischemic Stroke
09/01/2001 - 08/31/2003 (PI)
Parexel Sanofi Synthelabo

Epidemiologic Study of Acute Ischemic Stroke (ESIS)
09/22/2000 - 07/31/2003 (PI)
Genentech, Inc.

Showing 10 of 12 results. Show All Results

New England Regional Coordinating Center for the NINDS Stroke Trials Network
09/30/2013 - 07/31/2018 (PI)
Mass General Hosp NIH-NINDS

MR WITNESS: A Phase IIa Safety Study of Intravenous Thrombolysis with Altephase in MRI-Selected P…
11/19/2014 - 12/31/2015 (PI)
Mass General Hosp Genentech

Insulin Resistance Intervention After Stroke Trial (IRIS)
09/15/2004 - 08/31/2015 (PI)
Yale University NIH-NINDS

Bumpus Project 4
02/01/2004 - 01/31/2014 (PI)
Bumpus Foundation

MR Rescue
06/01/2007 - 04/30/2013 (PI)
Univ of California, Los Angeles NIH-NINDS

MA Coverdell Stroke Registry Project
06/09/2005 - 06/30/2009 (PI)

A Randomized Trial of Unruptured Brain Arteriovenous (ARUBA)
01/13/2006 - 07/31/2008 (PI)
Columbia University NIH
U01 NS0514843-01

Bumpus Parkinson'S Project 1
02/01/2001 - 02/01/2006 (PI)
Bumpus Foundation

Bumpus Parkinson'S Project 2
02/01/2001 - 02/01/2005 (PI)
Bumpus Foundation

Clomethiazole Class-1 Stroke
07/01/1999 - 06/30/2001 (PI)
Parexel Intl Corp

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Yogendrakumar V, Ramsay T, Fergusson DA, Demchuk AM, Aviv RI, Rodriguez-Luna D, Molina CA, Silva Blas Y, Dzialowski I, Kobayashi A, Boulanger JM, Lum C, Gubitz G, Srivastava P, Roy J, Kase CS, Bhatia R, Hill MD, Selim M, Dowlatshahi D. Independent Validation of the Hematoma Expansion Prediction Score: A Non-contrast Score Equivalent in Accuracy to the Spot Sign. Neurocrit Care. 2019 May 23. PMID: 31123995.
  2. Aparicio HJ, Himali JJ, Satizabal CL, Pase MP, Romero JR, Kase CS, Beiser AS, Seshadri S. Temporal Trends in Ischemic Stroke Incidence in Younger Adults in the Framingham Study. Stroke. 2019 Jun; 50(6):1558-1560.View Related Profiles. PMID: 31084341.
  3. Micieli JA, Newman NJ, Kase CS, Biousse V. Teaching Video NeuroImages: Opsoclonus in anti-DPPX encephalitis. Neurology. 2019 May 07; 92(19):e2298. PMID: 31061220.
  4. Rist PM, Buring JE, Ridker PM, Kase CS, Kurth T, Rexrode KM. Lipid levels and the risk of hemorrhagic stroke among women. Neurology. 2019 May 07; 92(19):e2286-e2294.View Related Profiles. PMID: 30971484.
  5. Ziai WC, McBee N, Lane K, Lees KR, Dawson J, Vespa P, Thompson RE, Mendelow AD, Kase CS, Carhuapoma JR, Thompson CB, Mayo SW, Reilly P, Janis S, Anderson CS, Harrigan MR, Camarata PJ, Caron JL, Zuccarello M, Awad IA, Hanley DF. A randomized 500-subject open-label phase 3 clinical trial of minimally invasive surgery plus alteplase in intracerebral hemorrhage evacuation (MISTIE III). Int J Stroke. 2019 Apr 03; 1747493019839280. PMID: 30943878.
  6. Hanley DF, Thompson RE, Rosenblum M, Yenokyan G, Lane K, McBee N, Mayo SW, Bistran-Hall AJ, Gandhi D, Mould WA, Ullman N, Ali H, Carhuapoma JR, Kase CS, Lees KR, Dawson J, Wilson A, Betz JF, Sugar EA, Hao Y, Avadhani R, Caron JL, Harrigan MR, Carlson AP, Bulters D, LeDoux D, Huang J, Cobb C, Gupta G, Kitagawa R, Chicoine MR, Patel H, Dodd R, Camarata PJ, Wolfe S, Stadnik A, Money PL, Mitchell P, Sarabia R, Harnof S, Barzo P, Unterberg A, Teitelbaum JS, Wang W, Anderson CS, Mendelow AD, Gregson B, Janis S, Vespa P, Ziai W, Zuccarello M, Awad IA. Efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral haemorrhage evacuation (MISTIE III): a randomised, controlled, open-label, blinded endpoint phase 3 trial. Lancet. 2019 Mar 09; 393(10175):1021-1032. PMID: 30739747.
  7. Shoamanesh A, Salloway S, Kase CS. Are lobar microbleeds of diagnostic value in the community? Neurology. 2019 Jan 15; 92(3):121-122. PMID: 30568006.
  8. Satizabal CL, Samieri C, Davis-Plourde KL, Voetsch B, Aparicio HJ, Pase MP, Romero JR, Helmer C, Vasan RS, Kase CS, Debette S, Beiser AS, Seshadri S. APOE and the Association of Fatty Acids With the Risk of Stroke, Coronary Heart Disease, and Mortality. Stroke. 2018 Dec; 49(12):2822-2829.View Related Profiles. PMID: 30571417.
  9. Kasner SE, Kase CS, Turan TN, Rowley HA, Andersen G, Iversen HK, Roine RO, Messé SR, Volpi J, Søndergaard L, Rhodes JF, Sjöstrand C. Characterization of Recurrent Strokes With and Without Patent Foramen Ovale Closure. J Am Coll Cardiol. 2018 Nov 13; 72(20):2542-2544. PMID: 30442299.
  10. Yogendrakumar V, Smith EE, Demchuk AM, Aviv RI, Rodriguez-Luna D, Molina CA, Silva Blas Y, Dzialowski I, Kobayashi A, Boulanger JM, Lum C, Gubitz G, Padma V, Roy J, Kase CS, Bhatia R, Ali M, Lyden P, Hill MD, Dowlatshahi D. Lack of Early Improvement Predicts Poor Outcome Following Acute Intracerebral Hemorrhage. Crit Care Med. 2018 04; 46(4):e310-e317. PMID: 29303797.
Showing 10 of 203 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 198 publications over 39 distinct years, with a maximum of 12 publications in 2017

Contact for Mentoring:

75 E. Newton St Collamore Building
Boston MA 02118
Google Map

Kase's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department